HRP20171978T1 - Proizvodnja i karakterizacija potpuno humanih terapeutskih antitijela dobivenih hucal gold tehnologijom, specifičnih za humani cd38 - Google Patents
Proizvodnja i karakterizacija potpuno humanih terapeutskih antitijela dobivenih hucal gold tehnologijom, specifičnih za humani cd38 Download PDFInfo
- Publication number
- HRP20171978T1 HRP20171978T1 HRP20171978TT HRP20171978T HRP20171978T1 HR P20171978 T1 HRP20171978 T1 HR P20171978T1 HR P20171978T T HRP20171978T T HR P20171978TT HR P20171978 T HRP20171978 T HR P20171978T HR P20171978 T1 HRP20171978 T1 HR P20171978T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- cells
- human
- cell
- seq
- Prior art date
Links
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title 1
- 239000010931 gold Substances 0.000 title 1
- 229910052737 gold Inorganic materials 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 14
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 13
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 210000003743 erythrocyte Anatomy 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 244000309715 mini pig Species 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 208000014951 hematologic disease Diseases 0.000 claims 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 102000052645 human CD38 Human genes 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000001638 cerebellum Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 210000002741 palatine tonsil Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000005267 prostate cell Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
Claims (15)
1. Humano specifično anti-CD38 antitijelo koje sadrži:
(i) H-CDR1, H-CDR2 i H-CDR3 regiju prikazanu u sekvenci SEQ ID NO: 21, i L-CDR1, L-CDR2 i L-CDR3 regiju prikazanu u sekvenci SEQ ID NO: 51;
(ii) varijabilni teški lanac sekvence SEQ ID NO: 21, i varijabilni laki lanac sekvence SEQ ID NO: 51; ili
(iii) varijabilni teški lanac kodiran sekvencom SEQ ID NO: 6, i varijabilni laki lanac kodiran sekvencom SEQ ID NO: 36.
2. Antitijelo prema patentnom zahtjevu 1, naznačeno time što antitijelo predstavlja IgG, poželjno IgG1.
3. Kompozicija nukleinske kiseline koja sadrži sekvencu nukleinske kiseline ili mnoštvo sekvenci nukleinske kiseline koje kodiraju antitijelo prema patentnom zahtjevu 1 ili 2.
4. Vektorska kompozicija koja sadrži vektor ili mnoštvo vektora koji sadrže sekvencu nukleinske kiseline, ili mnoštvo sekvenci nukleinske kiseline, prema patentnom zahtjevu 3.
5. Stanica koja sadrži vektorsku kompoziciju prema patentnom zahtjevu 4, gdje je stanica izborno bakterijska stanica ili stanica sisavca.
6. Farmaceutska kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 2 i farmaceutski prihvatljiv nosač ili ekscipijens.
7. Antitijelo prema patentnom zahtjevu 1 ili 2 za upotrebu u liječenju hematološke bolesti ili inflamatorne bolesti.
8. Farmaceutska kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 2 i farmaceutski prihvatljiv nosač ili ekscipijens za upotrebu u liječenju hematološke bolesti ili inflamatorne bolesti.
9. Antitijelo, za upotrebu prema patentnom zahtjevu 7 ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 8, naznačena time što je navedena hematološka bolest izabrana s liste na kojoj se nalaze multipli mijеlom, kronična limfocitna leukemija, kronična mijeloidna leukemija, akutna mijeloidna leukemija i akutna limfocitna leukemija.
10. Antitijelo, za upotrebu prema patentnom zahtjevu 7 ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 8, naznačena time što je navedena inflamatorna bolest izabrana sa liste na kojoj se nalazе reumatoidni artritis i sistemski lupus eritematozus.
11. In vitro postupak za indukciju specifičnog uništavanja tumorskih stanica koje eksprimiraju CD38, naznačen time što se navedeno specifično uništavanje odvija putem križnog vezivanja CD38, koje obuhvaća korak inkubacije navedenih stanica u prisutnosti dovoljne količine antitijela prema patentnom zahtjevu 1 ili 2.
12. Postupak za detekciju specifičnog uništavanja tumorskih stanica koje eksprimiraju CD38, putem križnog vezivanja CD38, kod subjekta kod koga je primijenjeno antitijelo prema patentnom zahtjevu 1 ili 2, koje obuhvaća korak in vitro detekcije specifične aktivnosti uništavanja kod navedenog antitijela, gdje tumorske stanice izborno potiču od čovjeka, mini-svinje ili zeca.
13. Postupak za detekciju prisustva CD38 u tkivu ili u stanici koja potiče od mini-svinje dovedenој u kontakt sa antitijelom prema patentnom zahtjevu 1 ili 2, koje obuhvaća korak in vitro detekcije specifičnog vezivanja navedenog antitijela za navedene CD38 stanice mini-svinje, gdje je navedeno antitijelo takođe sposobno da se specifično veže za CD38 humanog porekla, pri čemu je izborno, CD38 poreklom od mini-svinje, sadržan u tipu izolovane stanice izabranom iz grupe koja se sastoji od monocita periferne krvi, eritrocita, limfocita, timocita, mišićne stanice, stanice cerebeluma, stanice pankreasa, stanice limfnog čvora, stanice tonzila, stanice slezine, stanice prostate, stanice kože i stanice retine.
14. Postupak za detekciju CD38 u eritrocitu koji eksprimira CD38 dovedenom u kontakt sa antitijelom prema patentnom zahtjevu 1 ili 2, koje obuhvaća korak in vitro detekcije specifičnog vezivanja navedenog antitijela za navedene eritrocite koji eksprimiraju CD38, naznačen time što je navedeno antitijelo takođe sposobno da se specifično veže za humani CD38 iz stanice ili tkiva koje nisu humani eritrociti, gdje je izborno antitijelo takođe sposobno da se specifično veže za humani CD38 iz stanice koja je humani limfocit.
15. Dijagnostička kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 2 i prihvatljiv nosač ili ekscipijens
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72529705P | 2005-10-12 | 2005-10-12 | |
EP14196972.5A EP2860192B1 (en) | 2005-10-12 | 2006-10-12 | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171978T1 true HRP20171978T1 (hr) | 2018-04-06 |
Family
ID=37467440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171978TT HRP20171978T1 (hr) | 2005-10-12 | 2017-12-20 | Proizvodnja i karakterizacija potpuno humanih terapeutskih antitijela dobivenih hucal gold tehnologijom, specifičnih za humani cd38 |
Country Status (29)
Country | Link |
---|---|
US (6) | US8088896B2 (hr) |
EP (3) | EP3284756B1 (hr) |
JP (2) | JP5362359B2 (hr) |
KR (4) | KR101512853B1 (hr) |
CN (4) | CN103554259B (hr) |
AR (2) | AR055191A1 (hr) |
AU (1) | AU2006301446B2 (hr) |
BR (1) | BRPI0618399B1 (hr) |
CA (1) | CA2625681C (hr) |
CY (1) | CY1119722T1 (hr) |
DK (1) | DK2860192T3 (hr) |
ES (1) | ES2653664T3 (hr) |
HK (2) | HK1122822A1 (hr) |
HR (1) | HRP20171978T1 (hr) |
HU (1) | HUE035250T2 (hr) |
IL (1) | IL190665B (hr) |
LT (1) | LT2860192T (hr) |
ME (1) | ME02886B (hr) |
NO (1) | NO344961B1 (hr) |
NZ (1) | NZ566915A (hr) |
PL (1) | PL2860192T3 (hr) |
PT (1) | PT2860192T (hr) |
RS (1) | RS56677B1 (hr) |
RU (1) | RU2425841C2 (hr) |
SG (1) | SG10201400973XA (hr) |
SI (1) | SI2860192T1 (hr) |
TW (1) | TWI428444B (hr) |
WO (1) | WO2007042309A2 (hr) |
ZA (1) | ZA200803208B (hr) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
CN103554259B (zh) | 2005-10-12 | 2016-05-18 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
PE20120259A1 (es) | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
KR101827332B1 (ko) | 2008-12-12 | 2018-02-09 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-igf 항체 |
US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
ES2617446T3 (es) * | 2010-09-27 | 2017-06-19 | Morphosys Ag | Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
JP2014526886A (ja) * | 2011-07-15 | 2014-10-09 | モルフォシス・アー・ゲー | マクロファージ遊走阻止因子(mif)とd−ドーパクロームトートメラーゼ(d−dt)に交差反応性がある抗体 |
US20130122005A1 (en) | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
JP6184965B2 (ja) | 2011-10-28 | 2017-08-23 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | ポリペプチド構築物およびその使用 |
ES2728278T3 (es) | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
JP6286757B2 (ja) | 2012-04-23 | 2018-03-07 | ジーンフロンティア株式会社 | 抗ヒトcd69抗体、及びその医薬用途 |
CN104684552B (zh) | 2012-09-25 | 2018-08-07 | 莫佛塞斯公司 | 组合及其用途 |
ES2621377T3 (es) | 2012-11-05 | 2017-07-03 | Morphosys Ag | Anticuerpo marcado radiactivamente y usos del mismo |
CA2890862C (en) | 2012-11-09 | 2021-10-12 | Genefrontier Corporation | Anti-adam28 antibody for treating cancer |
SI2943511T1 (sl) | 2013-01-14 | 2020-01-31 | Xencor, Inc. | Novi heterodimerni proteini |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
CN105407921A (zh) * | 2013-03-13 | 2016-03-16 | 赛诺菲 | 包含抗cd38抗体和卡非佐米的组合物 |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
KR102094022B1 (ko) * | 2013-04-29 | 2020-03-30 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-cd38 항체 및 감쇠 인터페론 알파-2b와의 융합체 |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
JP5892117B2 (ja) * | 2013-07-17 | 2016-03-23 | 横河電機株式会社 | フィールド機器及び通信システム |
CN103513040B (zh) * | 2013-10-16 | 2015-03-11 | 常晓天 | 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用 |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
SG10202008629XA (en) | 2014-03-28 | 2020-10-29 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
SG11201700790XA (en) | 2014-08-03 | 2017-02-27 | Pogotec Inc | Wearable camera systems and apparatus and method for attaching camera systems or other electronic devices to wearable articles |
JP6707531B2 (ja) | 2014-09-09 | 2020-06-10 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体による併用療法 |
MX2017005481A (es) | 2014-10-29 | 2017-10-26 | Teva Pharmaceuticals Australia Pty Ltd | Variantes de interferon a2b. |
MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
NZ732144A (en) | 2014-11-26 | 2020-04-24 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
AU2015353416C1 (en) | 2014-11-26 | 2022-01-27 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CD38 |
CN107406506A (zh) * | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | 用于治疗急性髓系白血病的抗cd38抗体 |
CA2978399C (en) | 2015-03-06 | 2021-08-31 | Genefrontier Corporation | Anti-human membrane-type adam28 antibody |
US9951144B2 (en) * | 2015-04-08 | 2018-04-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD38 |
RS61668B1 (sr) | 2015-05-13 | 2021-04-29 | Morphosys Ag | Lečenje multiplog mijeloma (mm) |
EA201792546A1 (ru) | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
CA2990406A1 (en) * | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
RS65347B1 (sr) | 2015-06-24 | 2024-04-30 | Janssen Biotech Inc | Imunomodulacija i tretman čvrstih tumora antitelima koja specifično vezuju cd38 |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
HRP20220680T1 (hr) | 2015-11-03 | 2022-07-08 | Janssen Biotech, Inc. | Potkožne formulacije protutijela anti-cd38 i njihove uporabe |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
AU2017226960B2 (en) | 2016-03-04 | 2024-03-21 | Morphosys Ag | Clinical assessment of M-protein response in multiple myeloma |
CN116217731A (zh) | 2016-04-22 | 2023-06-06 | 艾科赛扬制药股份有限公司 | Alk7结合蛋白及其用途 |
KR20230054508A (ko) | 2016-06-14 | 2023-04-24 | 젠코어 인코포레이티드 | 이중특이적 체크포인트 억제제 항체 |
US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
CN116063545A (zh) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
EP3487506A1 (en) | 2016-07-20 | 2019-05-29 | Hybrigenics SA | Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer |
JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
CA3041183A1 (en) | 2016-11-02 | 2018-05-11 | Engmab Sarl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
CN110494445B (zh) | 2017-01-06 | 2023-10-20 | Abl生物公司 | 抗α-SYN抗体及其用途 |
US11780930B2 (en) | 2017-06-08 | 2023-10-10 | Black Belt Therapeutics Limited | CD38 modulating antibody |
CA3072296A1 (en) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 antibody |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
JP2020533362A (ja) | 2017-09-13 | 2020-11-19 | テネオバイオ, インコーポレイテッド | エクト酵素に結合する重鎖抗体 |
US20200255526A1 (en) | 2017-09-14 | 2020-08-13 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
KR20200089666A (ko) | 2017-10-25 | 2020-07-27 | 악셀레론 파마 인코포레이티드 | Alk7 결합 단백질 및 그의 용도 |
US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
CN111542545A (zh) | 2017-11-03 | 2020-08-14 | 索伦托治疗有限公司 | Cd38定向嵌合抗原受体构建体 |
EP3725806A4 (en) * | 2017-12-14 | 2022-03-30 | ABL Bio Inc. | BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE |
CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
EP4144372A3 (en) | 2018-03-21 | 2023-06-14 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
US12048745B2 (en) | 2018-05-01 | 2024-07-30 | Augusta University Research Institute, Inc. | Methods for detecting and reversing immune therapy resistance |
US12012461B2 (en) | 2018-05-16 | 2024-06-18 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics |
EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
MA52742A (fr) | 2018-06-09 | 2021-04-14 | Boehringer Ingelheim Int | Anticorps bispécifiques dll3-cd3 |
WO2019245616A1 (en) * | 2018-06-20 | 2019-12-26 | Sorrento Therapeutics, Inc. | Variant antibody that binds cd38 |
US20240254252A1 (en) | 2018-07-13 | 2024-08-01 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
BR112020026432A2 (pt) | 2018-07-13 | 2021-03-23 | Genmab A/S | variante de anticorpo, ácido nucleico isolado, vetor de expressão, ácido nucleico, combinação de ácidos nucleicos, veículo de dispensação, célula hospedeira recombinante, métodos para produção de uma variante de um anticorpo, para aumentar pelo menos uma função efetora de um anticorpo parental e para tratar uma doença, anticorpo, composição, composição farmacêutica, e, variante de anticorpo para uso |
WO2020052546A1 (zh) | 2018-09-11 | 2020-03-19 | 江苏恒瑞医药股份有限公司 | 抗cd38抗体、其抗原结合片段及医药用途 |
CN109293773B (zh) * | 2018-09-25 | 2020-09-04 | 上海邦耀生物科技有限公司 | 靶向cd38蛋白的抗体、嵌合抗原受体和药物 |
CN113195540A (zh) | 2018-10-17 | 2021-07-30 | 詹森生物科技公司 | 提供皮下施用抗cd38抗体的方法 |
JP2022505445A (ja) | 2018-10-26 | 2022-01-14 | テネオバイオ, インコーポレイテッド | Cd38に結合する重鎖抗体 |
JP2022513018A (ja) | 2018-11-13 | 2022-02-07 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体の生成中の微量金属の制御 |
MX2021007047A (es) | 2018-12-14 | 2021-10-26 | Morphosys Ag | Formulaciones de anticuerpos. |
CN113614107A (zh) * | 2019-01-23 | 2021-11-05 | Encefa公司 | Cd31竞争剂及其用途 |
CN113574071A (zh) * | 2019-03-15 | 2021-10-29 | 莫佛塞斯公司 | 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物 |
US20220306762A1 (en) * | 2019-07-03 | 2022-09-29 | Crystal Bioscience Inc. | Anti-cd38 antibody and methods of use thereof |
EP4031166A1 (en) * | 2019-09-18 | 2022-07-27 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 |
TW202128756A (zh) | 2019-10-02 | 2021-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
GB201916150D0 (en) | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
JPWO2021112196A1 (hr) * | 2019-12-05 | 2021-06-10 | ||
US20220372162A1 (en) | 2019-12-18 | 2022-11-24 | TeneoFour, Inc. | Pct/us2020/066088 |
CA3165660A1 (en) | 2020-01-16 | 2021-07-22 | Genmab A/S | Formulations of cd38 antibodies and uses thereof |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
AU2021276332A1 (en) | 2020-05-19 | 2022-11-17 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
CN111808193B (zh) * | 2020-06-30 | 2022-04-05 | 源道隆(苏州)医学科技有限公司 | 可结合人cd38的纳米抗体及其应用 |
CN113861292A (zh) * | 2020-06-30 | 2021-12-31 | 百奥泰生物制药股份有限公司 | 抗cd40抗体或抗原结合片段及其应用 |
KR20230166150A (ko) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
JP2023546229A (ja) | 2020-10-21 | 2023-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼の疾患の処置のためのアゴニスト性TrkB結合分子 |
CA3204187A1 (en) | 2021-01-14 | 2022-07-21 | Stefan Steidl | Anti-cd38 antibodies and their uses |
US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗cd38抗體 |
KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
WO2022263507A1 (en) | 2021-06-17 | 2022-12-22 | Boehringer Ingelheim International Gmbh | Novel tri-specific binding molecules |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
AU2022320793A1 (en) | 2021-07-28 | 2024-02-01 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
AU2022380155A1 (en) | 2021-11-03 | 2024-06-20 | Janssen Biotech, Inc. | Corticosteriod reduction in treatment with anti-cd38 antibodies |
CN116514974A (zh) * | 2022-01-30 | 2023-08-01 | 百奥泰生物制药股份有限公司 | 抗cd28抗体及其应用 |
WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
US20240052065A1 (en) | 2022-07-15 | 2024-02-15 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
WO2024095173A1 (en) | 2022-11-02 | 2024-05-10 | Janssen Biotech, Inc. | Methods of treating cancers |
WO2024153768A1 (en) | 2023-01-20 | 2024-07-25 | Boehringer Ingelheim International Gmbh | Il-12 fc fusion proteins |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5075108A (en) * | 1986-01-03 | 1991-12-24 | Consolidated Pharmaceuticals, Limited | Melphalan derivatives |
SU1595902A1 (ru) * | 1988-06-30 | 1990-09-30 | Всесоюзный онкологический научный центр АМН СССР | Штамм гибридных культивируемых клеток животных MUS мUSсULUS L, используемый дл получени моноклональных антител к антигену СД38 кортикальных тимоцитов |
US5156951A (en) * | 1989-07-13 | 1992-10-20 | Becton Dickinson And Company | Detecting immunological changes in HIV infected patient samples |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
AU6123894A (en) | 1993-01-29 | 1994-08-15 | Board Of Trustees Of The Leland Stanford Junior University | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
US6555324B1 (en) | 1993-11-04 | 2003-04-29 | Becton Dickinson & Company | Method to distinguish hematopoietic progenitor cells |
US20020164788A1 (en) * | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
GB9424449D0 (en) * | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
ATE271128T1 (de) | 1995-05-11 | 2004-07-15 | Applied Research Systems | Inhibitoren der il-6 aktivitaet |
DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
US5594116A (en) | 1995-11-08 | 1997-01-14 | Promega Corporation | Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay |
JP4233608B2 (ja) * | 1996-10-15 | 2009-03-04 | 塩野義製薬株式会社 | 自己抗体測定方法 |
CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
GB9903664D0 (en) | 1999-02-17 | 1999-04-14 | Isis Innovation | Adjuvant and cell maturation agent |
JP2000316578A (ja) | 1999-05-12 | 2000-11-21 | Bml Inc | 糖尿病発症危険因子の検出方法 |
WO2001005950A2 (en) | 1999-07-20 | 2001-01-25 | Morphosys Ag | Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
US20020028488A1 (en) | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
EP1174440A1 (en) * | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
AU1331802A (en) | 2000-10-17 | 2002-04-29 | Trudeau Inst Inc | Cd38 modulated chemotaxis |
US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
US6892140B1 (en) | 2000-11-27 | 2005-05-10 | Enteron, Inc. | Immunogenic cancer peptides and uses thereof |
US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
ES2389251T3 (es) | 2000-12-19 | 2012-10-24 | Altor Bioscience Corporation | Animales transgénicos que comprenden un sistema inmunitario humanizado |
US20040081981A1 (en) | 2001-01-31 | 2004-04-29 | Toru Egashira | Method of detecting risk factor for onset of diabetes |
AU2002307494A1 (en) | 2001-04-24 | 2002-11-05 | Bayer Corporation | Human timp-1 antibodies |
US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
JP3665324B2 (ja) * | 2001-10-15 | 2005-06-29 | 麒麟麦酒株式会社 | 抗hla−dr抗体 |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7553926B2 (en) | 2002-04-23 | 2009-06-30 | Andrea Savarino | Compositions containing anti-HIV peptides and methods for use |
ES2263984T3 (es) * | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
EP1689435A4 (en) | 2003-10-22 | 2007-10-03 | Univ Rochester | ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS |
AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
DK1720907T3 (en) | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies as well as applications therefor |
EP1716176B1 (en) | 2004-02-13 | 2009-10-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cd38 splice variant and uses thereof |
KR101433381B1 (ko) | 2005-03-23 | 2014-10-02 | 젠맵 에이/에스 | 다발성 골수종의 치료를 위한 cd38에 대한 항체 |
JP2008535494A (ja) | 2005-04-07 | 2008-09-04 | サグレシュ ディスカバリー, インコーポレイテッド | 癌関連遺伝子(prlr) |
US20090123950A1 (en) | 2005-05-24 | 2009-05-14 | Morphosys Ag | Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38 |
CN103554259B (zh) | 2005-10-12 | 2016-05-18 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2205727B1 (en) | 2007-10-01 | 2015-06-24 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
WO2011045704A1 (en) | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
ES2617446T3 (es) * | 2010-09-27 | 2017-06-19 | Morphosys Ag | Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
CN104684552B (zh) * | 2012-09-25 | 2018-08-07 | 莫佛塞斯公司 | 组合及其用途 |
ES2621377T3 (es) * | 2012-11-05 | 2017-07-03 | Morphosys Ag | Anticuerpo marcado radiactivamente y usos del mismo |
US11920830B1 (en) | 2022-11-11 | 2024-03-05 | Russell Dwayne Mcnally | Tool and method for cleaning and draining a water heater |
-
2006
- 2006-10-12 CN CN201310494874.2A patent/CN103554259B/zh active Active
- 2006-10-12 LT LTEP14196972.5T patent/LT2860192T/lt unknown
- 2006-10-12 SI SI200632232T patent/SI2860192T1/en unknown
- 2006-10-12 TW TW095137628A patent/TWI428444B/zh active
- 2006-10-12 RS RS20171300A patent/RS56677B1/sr unknown
- 2006-10-12 KR KR1020087011301A patent/KR101512853B1/ko active IP Right Grant
- 2006-10-12 ES ES14196972.5T patent/ES2653664T3/es active Active
- 2006-10-12 KR KR1020137033870A patent/KR101472250B1/ko active IP Right Grant
- 2006-10-12 EP EP17193089.4A patent/EP3284756B1/en active Active
- 2006-10-12 NZ NZ566915A patent/NZ566915A/en unknown
- 2006-10-12 RU RU2008111882/10A patent/RU2425841C2/ru active
- 2006-10-12 KR KR1020147020460A patent/KR101574920B1/ko active IP Right Grant
- 2006-10-12 SG SG10201400973XA patent/SG10201400973XA/en unknown
- 2006-10-12 EP EP06806243A patent/EP1945671A2/en not_active Withdrawn
- 2006-10-12 CA CA2625681A patent/CA2625681C/en active Active
- 2006-10-12 WO PCT/EP2006/009889 patent/WO2007042309A2/en active Application Filing
- 2006-10-12 PL PL14196972T patent/PL2860192T3/pl unknown
- 2006-10-12 BR BRPI0618399-9A patent/BRPI0618399B1/pt active IP Right Grant
- 2006-10-12 CN CN201510918061.0A patent/CN106434683B/zh active Active
- 2006-10-12 EP EP14196972.5A patent/EP2860192B1/en active Active
- 2006-10-12 AR ARP060104476A patent/AR055191A1/es active IP Right Grant
- 2006-10-12 US US12/089,806 patent/US8088896B2/en active Active
- 2006-10-12 CN CN201310495574.6A patent/CN103554260A/zh active Pending
- 2006-10-12 PT PT141969725T patent/PT2860192T/pt unknown
- 2006-10-12 DK DK14196972.5T patent/DK2860192T3/en active
- 2006-10-12 CN CN2006800379242A patent/CN101287764B/zh active Active
- 2006-10-12 KR KR1020157034098A patent/KR20150139636A/ko not_active Application Discontinuation
- 2006-10-12 AU AU2006301446A patent/AU2006301446B2/en active Active
- 2006-10-12 JP JP2008534940A patent/JP5362359B2/ja active Active
- 2006-10-12 HU HUE14196972A patent/HUE035250T2/hu unknown
- 2006-10-12 ME MEP-2017-289A patent/ME02886B/me unknown
-
2008
- 2008-04-07 IL IL190665A patent/IL190665B/en active IP Right Grant
- 2008-04-11 ZA ZA200803208A patent/ZA200803208B/xx unknown
- 2008-04-25 NO NO20081972A patent/NO344961B1/no unknown
- 2008-12-30 HK HK08114074.2A patent/HK1122822A1/xx unknown
-
2011
- 2011-11-08 US US13/291,473 patent/US8486394B2/en active Active
-
2012
- 2012-11-08 JP JP2012246686A patent/JP5752667B2/ja active Active
-
2013
- 2013-06-14 US US13/918,199 patent/US9193799B2/en active Active
-
2014
- 2014-07-31 HK HK14107873.1A patent/HK1194398A1/zh unknown
-
2015
- 2015-10-08 US US14/877,958 patent/US10184005B2/en active Active
-
2016
- 2016-07-26 AR ARP160102271A patent/AR105490A2/es not_active Application Discontinuation
-
2017
- 2017-12-19 CY CY20171101331T patent/CY1119722T1/el unknown
- 2017-12-20 HR HRP20171978TT patent/HRP20171978T1/hr unknown
-
2018
- 2018-09-07 US US16/125,307 patent/US11059902B2/en active Active
-
2021
- 2021-06-09 US US17/343,163 patent/US11939395B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171978T1 (hr) | Proizvodnja i karakterizacija potpuno humanih terapeutskih antitijela dobivenih hucal gold tehnologijom, specifičnih za humani cd38 | |
Haas et al. | Integrin α7 is a functional marker and potential therapeutic target in glioblastoma | |
Enyindah-Asonye et al. | CD318 is a ligand for CD6 | |
JP5893559B2 (ja) | 新規な薬剤及びその使用 | |
RU2597831C2 (ru) | Анти-il1rap антитела и их применение при лечении людей | |
Brandtzaeg et al. | Regional specialization in the mucosal immune system: primed cells do not always home along the same track | |
Imhof et al. | CCN1/CYR61-mediated meticulous patrolling by Ly6Clow monocytes fuels vascular inflammation | |
Zhang et al. | Ongoing activation of autoantigen‐specific B cells in primary biliary cirrhosis | |
Sanchez-Martinez et al. | Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors | |
RU2015108348A (ru) | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения | |
Yoshida et al. | Reversible human TGF-β signal shifting between tumor suppression and fibro-carcinogenesis: Implications of Smad phospho-isoforms for hepatic epithelial-mesenchymal transitions | |
UA126802C2 (uk) | Композиція, що містить антигензв’язуючий домен, який зв'язується з tigit людини | |
JP6830471B2 (ja) | 抗ホスホリパーゼd4抗体 | |
JP2007504280A5 (hr) | ||
ATE482234T1 (de) | Antikörper gegen kdr, deren herstellung und verwendungen | |
RU2016123839A (ru) | Новые модуляторы и способы их применения | |
US8247186B2 (en) | Monoclonal antibodies and their use | |
ES2808947T3 (es) | Anticuerpos humanizados anti-BAG3 | |
Jiang et al. | Intact CD100–CD72 interaction necessary for TCR-induced T cell proliferation | |
Chitteti et al. | CD166 and regulation of hematopoiesis | |
Bunting et al. | Novel antagonist antibody to TLR3 blocks poly (I: C)-induced inflammation in vivo and in vitro | |
Choi et al. | Detection of mycoplasma infection in circulating tumor cells in patients with hepatocellular carcinoma | |
WO2020073917A1 (en) | Anti-bcma antibodies | |
JP6972030B2 (ja) | 抗n−アセチルグルコサミン及びn−アセチルガラクトサミンの抗体 | |
Théry et al. | ISEV2018 abstract book |